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Prevention and Control (ECDC), Stockholm, SwedenAbstractAn aggregation of moxiﬂoxacin-resistant Clostridium difﬁcile ribotype 231 (RT231) isolates was ﬁrst identiﬁed in the county of Stockholm in
2008, and by the end of 2015 isolates of RT231 had spread to 13 of 21 Swedish counties. We investigated the epidemiology of C. difﬁcile
RT231 in Sweden between 2006 and 2015 using whole genome sequencing (WGS) and evaluated whether its emergence could be
associated with extended moxiﬂoxacin use. We performed WGS and phylogenetic analysis of 51 C. difﬁcile RT231 strains isolated in
Sweden over a 10-year period. We also calculated the county-speciﬁc prescription rates for moxiﬂoxacin between 2005 and 2015. Using
WGS and detailed single nucleotide polymorphism analysis, we demonstrated three divergent sublineages of moxiﬂoxacin-resistant
C. difﬁcile RT231 in Sweden from 2008 to 2015. A set of closely related RT231 was identiﬁed in hospitals located in the counties of
Stockholm and Uppsala in 2008. Another set of RT231 isolates was found in four different counties in the Uppsala–Örebro Health Care
Region. A gradual drop in moxiﬂoxacin use in the county of Stockholm coincided with a reduction of RT231 in the area. However,
RT231 continued to be frequent in surrounding counties including Uppsala, a county that also had the highest moxiﬂoxacin prescription
rates. We demonstrated frequent transmission of C. difﬁcile RT231 within and between counties, indicating the importance of careful
monitoring of hospitalized individuals infected with moxiﬂoxacin-resistant C. difﬁcile as well as the need for a strict moxiﬂoxacin
prescription policy.
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E-mail: kristina.rizzardi@folkhalsomyndigheten.seIntroductionClostridium difﬁcile, a Gram-positive and spore-forming anaer-
obic bacillus, is a leading cause of healthcare-associated diar-
rhoea in industrialized countries [1]. Transmission occurs
primarily in healthcare facilities, where exposure to antibiotics
and environmental contamination by C. difﬁcile spores are
common. Antibiotic treatment, advanced age (>65 years),
comorbidities and hospitalization have been identiﬁed as major
risk factors for C. difﬁcile infection (CDI) [2]. However,w Microbe and New Infect 2016; 14: 58–66
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p://dx.doi.org/10.1016/j.nmni.2016.09.002antimicrobial therapy is the single most important risk factor
for CDI. It leads to the disruption of the normal intestinal ﬂora,
creating favourable conditions for acquisition and proliferation
of C. difﬁcile [3]. Clindamycin, amoxicillin, third-generation
cephalosporins and more recently ﬂuoroquinolones have
been shown to be associated with a particularly high risk of
developing CDI [4].
The ﬁrst whole genome sequence of C. difﬁcile was obtained
in 2006; sequencing revealed a large circular chromosome of
4 290 252 bp likely coding for 3776 proteins and an extrac-
ircular plasmid 7881 bp in size [5]. Several other complete or
almost complete genomic sequences have since been obtained
[6]. These studies have shown that the C. difﬁcile genome
contains a high proportion (over 10%) of mobile genetic ele-
ments including bacteriophages, repeat elements and genomic
islands, as well as transposable and conjugative elements.obiology and Infectious Diseases
nses/by-nc-nd/4.0/)
NMNI Harvala et al. C. difﬁcile ribotype 231 in Sweden 59Several typing methods have been used to study the
epidemiology, genetic diversity and evolution of C. difﬁcile. In
Europe PCR ribotyping has been one of the most widely
adopted methods, and over 600 C. difﬁcile ribotypes have
been identiﬁed. A particular subtype, C. difﬁcile ribotype 027,
has been associated with severe disease and hospital out-
breaks in North America and Europe [7–9]. Global emer-
gence of this moxiﬂoxacin-resistant C. difﬁcile type 027
prompted establishment of national surveillance programs in
several European countries [10–12]. As a result of national
surveillance, a clonal aggregation of a newly emerging,
moxiﬂoxacin-resistant C. difﬁcile ribotype 231 (RT231) was
uncovered in Sweden in 2008 [12]. This type was initially
geographically limited to the Stockholm area, where over 70%
of all moxiﬂoxacin-resistant C. difﬁcile strains were charac-
terized as RT231 in 2008 (125/144) [12]. Despite an
increasing awareness of CDI and enhanced infection control
policies, RT231 has continued to spread in Sweden; by the
end of the year 2015 it had been identiﬁed in 13 of 21
counties, suggesting interhospital transmission and possible
local outbreaks [13].
Although no studies have shown whether moxiﬂoxacin use
implies higher risk for CDI than other commonly used antibi-
otics [14], the restriction of moxiﬂoxacin use has been asso-
ciated with a reduction in the number of CDIs in Northern
Ireland and England [15,16]. Similarly, a study from Vienna
demonstrated that enhanced antibiotic stewardship, including
restriction of moxiﬂoxacin use, was associated with a reduction
in the number of CDI in population with a high rate of
multidrug-resistant C. difﬁcile [17].
We used whole genome sequencing (WGS) and phyloge-
netic analysis to investigate the spread of this newly emerging
moxiﬂoxacin-resistant C. difﬁcile RT231 in Sweden between
2006 and 2015. We also evaluated the potential associationTABLE 1. Total number of Clostridium difﬁcile isolates collected in
ribotype 231 (RT231) isolates included in study
Year
All C. difﬁcile
isolates
Moxiﬂoxacin-resistant
isolates
Moxiﬂoxacin-resistant
RT231
Moxiﬂo
RT231
2006 13 1 1 Unknown
2007 22 6 6 Unknown
2008 586 586 125 Unknown
2009 393 57 8 1
2010 335 53 5 1
2011 418 59 8 0
2012 423 87 16 1
2013 459 60 8 0
2014 391 57 6 0
2015 413 43 3 0
Total 3446 1002 186 3
aIn 2006 C. difﬁcile typing was performed only for diagnostic purposes, and in 2007–2008 o
© 2016 The Author(s). Published by Elsevier Ltd on behal
This is an open access articbetween the extent of moxiﬂoxacin prescription rates and the
epidemiology of RT231.Materials and MethodsCollection of C. difﬁcile isolates
All 189 C. difﬁcile RT231 isolates identiﬁed in Sweden between
2006 and 2015 were included in this study (Table 1). The
strains collected between 2009 and 2015 were obtained
through the national surveillance program for C. difﬁcile; before
2009 samples were obtained via a nationwide surveillance study
[12]. Date of sample and county of diagnostic laboratory were
collected as previously described [12]. PCR ribotyping between
2006 and 2012 was performed by a gel-based method [12] and
between 2013 and 2015 by capillary-gel electrophoresis [18].
Fifty-one of 189 C. difﬁcile RT231 isolates were selected for
WGS. All moxiﬂoxacin-sensitive strains were included, and
moxiﬂoxacin-resistant isolates were selected to cover each
isolation region per year to obtain a geographically and
temporally representative sample collection. The number of
patients or cases of CDI was not available.
Antimicrobial susceptibility assays
Isolates were grown on Mueller-Hinton fastidious agar, and
minimum inhibitory concentration (MIC) values for moxi-
ﬂoxacin, erythromycin, clindamycin, metronidazole and van-
comycin were determined using Etests (bioMérieux, Marcy
l’Etoile, France) as described previously [12]. The epidemiologic
cutoff breakpoints for resistance were as follows: metronida-
zole MIC >2 mg/L, vancomycin MIC >2 mg/L, erythromycin
MIC >2 mg/L, clindamycin MIC >16 mg/L and moxiﬂoxacin MIC
>4 mg/L, according to the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST).Sweden between 2006 and 2015, and numbers of C. difﬁcile
xacin-sensitive RT231 isolates included in study (frequency of strains
included per year)
a 1 (1/1)
a 1 (1/6)
a 11 (11/125)
6 (6/9)
6 (6/6)
6 (6/8)
7 (7/17)
4 (4/8)
6 (6/6)
3 (3/3)
51 (51/189)
nly moxiﬂoxacin-resistant C. difﬁcile strains were collected.
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Isolates were recultured on blood agar plates, inoculated into
sterile peptone yeast liquid medium with 0.5 mg/mL cysteine
and grown overnight anaerobically at 35°C. Cells were pelleted,
suspended into lysis buffer (1 mM Tris, 0.1 mM EDTA, 0.1%
Triton-X and 20 mg/mL lysozyme) with proteinase K (180 μL of
buffer and 20 μL of proteinase K (20 μL/mL)) and incubated for
18 hours at 56°C. Genomic DNA was extracted using Mag-
Attract DNA Mini M48 Kit and Biorobot M48 according to the
manufacturer’s recommendations (Qiagen, Sollentuna, Swe-
den). DNA was eluted into a ﬁnal volume of 100 μL.
Whole genome sequencing
WGS was performed using the Ion Torrent platform, aiming to
read lengths of 200 bp and coverage of 30×. The sequence data
were analysed by CLC Assembly Cell 4.4.2 software. Sequence
type (ST) was determined for comparison using mapping and
the Basic Local Alignment Search Tool (BLAST) against the
C. difﬁcile multilocus sequence typing (MLST) database (http://
pubmlst.org/cdifﬁcile/). Strain MX213 was used as the refer-
ence genome for single nucleotide polymorphism (SNP) anal-
ysis. The raw data were mapped to the reference genome, and
variants were called. Positions with low coverage (<10) or
ambiguous calls (<90%) in one or more samples were ﬁltered
out. SNPs within 500 bp of each other were ﬁltered out as
single events from the SNPs in the phylogenetic analysis to
remove nonrandomly distributed mutations; these are collec-
tively termed recombination events. These mutations are
considered a single event for the purpose of genetic distance. A
minimum spanning tree was constructed on the basis of the all
SNP differences. The analysis was repeated excluding the four
nonrelated strains; the remaining individual SNP positions were
compiled into an alignment and used for phylogenetic analysis.
Phylogenetic analysis
Neighbour-joining phylogenetic trees were constructed on the
basis of the SNP alignments using MEGA 6.0 and 100 bootstrap
replicates. Metadata including year of isolation and geographical
location were transferred to the reconstructed tree. The
genomic relatedness of isolates was assessed by SNP analysis:
up to three individual SNPs per genome was expected to be
seen between related isolates collected up to 1 year apart,
whereas strains which differed more than ten individual SNPs
were classiﬁed as unrelated.
Antibiotic data
Data on moxiﬂoxacin prescriptions were obtained from Apo-
tekens Service AB (2003–2013) and from the Swedish eHealth
Agency (2014–2015). The data include moxiﬂoxacin prescribed to
patients as well as sales to hospitals and other healthcare providers.© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Micr
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceResultsWhole genome sequencing
A total of 51 of 189 C. difﬁcile RT231 isolates selected for WGS
were geographically and temporally representative; they
included isolates from all 13 counties where RT231 strains had
been isolated over a 10-year period (Tables 1 and 2). An
average minimum coverage of 60.07 (range 20.52–120.13)
reads per nucleotide and an average genome length of 4.14
(range 3.92–4.30) Mbp were obtained for all samples.
No previous WGS data were available for C. difﬁcile RT231,
and thus the ﬁrst whole genome sequence of RT231 was ob-
tained by a de novo assembly of strain MOX213 (3.92 Mbp).
This was used as a reference genome in further analysis. MLST
data obtained from whole genome sequence representing
approximately 0.09% of the whole genome (3501 nt) were
almost consistent with ribotyping data; all studied isolates
belonged to ST133. One isolate (NT949), determined to be
PCR RT231 by a gel-based method, belonged to ST133, but
PCR ribotyping analysis by capillary-gel electrophoresis with
higher resolution suggested a new, unknown ribotype.
A total of 4091 nucleotide differences were identiﬁed within
the 51 isolates; 3225 nucleotide differences were classiﬁed as
recombination events, whereas the remaining 866 nucleotide
differences were classed as individual SNPs. The results are
presented in a minimal spanning tree in Fig. 1 (88.56% of the
genome was used as the dynamic core genome). A total of 3496
nucleotide differences distinguished four single isolates (three
moxiﬂoxacin-sensitive isolates NT049/Jönköping_2009,
NT513/VästraGötaland_2010 and NT1619/Skåne_2012 and
one moxiﬂoxacin-resistant isolate NT949/Norrbotten_2011)
from the remaining 47 isolates (all moxiﬂoxacin-resistant iso-
lates). A total of 2681 nucleotide differences out of 3496 were
ﬁltered as 447 recombination events. Within the remaining 47
isolates, ﬁve strains (MX405/Stockholm_2008, MX381/Stock-
holm_2008, NT422/Gotland_2009, NT116/Stockholm_2009
and NT099/Stockholm_2009) differed by 554 nucleotides from
the closest main cluster of 42 isolates. A total of 544 nucleotide
differences out of 554 were ﬁltered as three recombination
events.
Phylogenetic analysis
In order to study potential transmission of moxiﬂoxacin-
resistant C. difﬁcile RT231 between different counties during
the 10-year study period, a phylogenetic comparison of 47
strains based on the core genome SNP analysis was performed
(excluding the unrelated isolates NT049, NT513, NT949 and
NT1619). A total of 93.2% of the genome was used in the
analysis as the dynamic core genome. A total of 566 nucleotideobiology and Infectious Diseases, NMNI, 14, 58–66
nses/by-nc-nd/4.0/).
TABLE 2. Total number of Clostridium difﬁcile ribotype 231 (RT231) isolates collected in each healthcare region and county in
Sweden between 2006 and 2015
Healthcare region County 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Total
Stockholm Stockholm 1 6 119 5 1 2 1 135
Gotland 3 3
Uppsala–Örebro Uppsala 4 1 4 6 1 1 17
Södermanland 1 5 6 3 1 16
Västmanland 2 4 1 1 8
Dalarna 1 1
Örebro 1 1 2
Värmland 1 1
Gävleborg
North Norrbotten 1b 1
Västerbotten
Jämtland
Västernorrland
Southeast Östergotland
Jönköping 1a 1
Kalmar
West Västra Götaland 1a 1
Halland (partly)
South Kronoberg
Blekinge 2 2
Skåne 1a 1
Halland (partly)
Total 1 6 125 9 6 8 17 8 6 3 189
aThese C. difﬁcile RT231 isolates are moxiﬂoxacin sensitive.
bThis isolate was shown not to be PCR RT231.
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recombination events. The remaining 56 phylogenetically
representative individual SNPs were included in the phyloge-
netic analysis. SNP differences between isolates were small,
varying from zero to 11 SNPs.
Three main clusters could be identiﬁed. Seventeen isolates
collected between 2007 and 2012 in the counties of Stockholm,
Uppsala and Blekinge formed the ﬁrst cluster, with only 3 SNPs’
difference between them (cluster 1, Fig. 2). A clonal strain
(deﬁned as 1 SNP difference) was identiﬁed in ﬁve different
hospitals in the counties of Stockholm and Uppsala during 2008
and 2009. The remaining Stockholm isolates from 2008 and
2009 (n = 4; all from the same hospital) formed their own
bootstrap supported cluster together with a single isolate
identiﬁed in Gotland during the same time period (cluster 2,
Fig. 2). The third cluster was composed of the oldest isolate
identiﬁed in Stockholm in 2006, another Stockholm isolate
from 2008 and all the other isolates collected in Uppsala (n = 7),
Västmanland (n = 5), Södermanland (n = 8), Örebro (n = 2) and
Dalarna (n = 1), with a maximum difference of 3 SNPs between
the isolates (cluster 3, Fig. 2). A second clonal strain was
circulating in the counties of Uppsala, Södermanland, Väst-
manland and Örebro between 2009 and 2015.
Antimicrobial resistance
In total, 48 of the 51 C. difﬁcile RT231 isolates were resistant to
moxiﬂoxacin according to EUCAST epidemiologic cutoff MIC
breakpoints. All moxiﬂoxacin-resistant C. difﬁcile RT231 isolates
identiﬁed between 2009 and 2015 were also resistant to clin-
damycin and erythromycin. No isolate was resistant to© 2016 The Author(s). Published by Elsevier Ltd on behal
This is an open access articmetronidazole or vancomycin. All moxiﬂoxacin-resistant
strains harboured an amino acid substitution in the gyrA gene
(Thr82 > Ile); the unrelated moxiﬂoxacin-resistant NT949
strain had an additional amino acid substitution in the gyrB gene
(Asp426 > Asn). No other mutations within the GyrA or GyrB
genes were identiﬁed. We screened the isolates for the pres-
ence of the ermB gene known to confer macrolide and linco-
samide resistance. Interestingly all isolates carried most of the
TN5398 transposon with a deletion of the ermB locus (Fig. 3).
All isolates were also negative for the other predominant erm
genes found in anaerobes (A, C, E, F and Q) [19]. Both sensitive
and resistant strains carried the cme gene, which encodes an
efﬂux pump similar to mefA, shown to confer erythromycin
resistance [20]. Furthermore, the 23S rRNA sequences were
analysed, but no differences were found between sensitive and
resistant strains. A mutation in the rplD gene (G211A,
Ala71 > Thr), encoding the L4 protein of the 50S ribosomal
subunit, was found in 25 of 47 resistant isolates, with all isolates
belonging to cluster 3. All ﬁve isolates in cluster 2, on the other
hand, carried a mutation in the rplV gene (G313A, Val105 > Ile)
encoding the L22 protein of the 50S ribosomal subunit.
Prescription of moxiﬂoxacin in Sweden between 2005
and 2015
To evaluate a possible link between moxiﬂoxacin consumption
and the spread of RT231, we analysed the county-speciﬁc
consumption rates for moxiﬂoxacin. The mean community
prescription rate of moxiﬂoxacin in Sweden decreased from 9.2
deﬁned daily doses (DDD) per 1000 inhabitants per year in
2003 to 4.46 in 2015, whereas the mean hospital prescriptionf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 14, 58–66
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FIG. 1. Minimum spanning tree of Clostridium difﬁcile RT231 isolates included in study. Isolates in red bubbles are moxiﬂoxacin sensitive; isolate in
dashed bubble belongs to ST131 but not RT231. SNP differences are shown next to branches, recombination events are marked R, and total number of
nucleotide differences is shown in parentheses. Length of branches is not relative to relationship distance.
62 New Microbes and New Infections, Volume 14 Number C, November 2016 NMNIrates increased from 1.17 DDD per 1000 inhabitants per year
in 2003 to 2.59 in 2015. The differences in the community
moxiﬂoxacin prescription between counties became smaller
over time (range in community 0.24–23.26 (2003) and
0.54–11.53 (2014) DDD per 1000 inhabitants per year),
whereas the opposite was seen in the hospital prescription
rates between counties (range in hospital 0.13–3.25 (2003) and
0.18–9.13 (2014) DDD per 1000 inhabitants per year). In 2014
the highest prescription rates, both in community and hospital
settings, were identiﬁed in Uppsala county (11.53 and 9.13
DDD per 1000 inhabitants per year, respectively) (Fig. 4).© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Micr
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceHospital use of moxiﬂoxacin was also high in Södermanland
county in 2014 (9.02 DDD per 1000 inhabitants per year). Two
other counties, Jönköping and Kronoberg, were noted also to
have had high overall prescription rates of moxiﬂoxacin in both
community and hospital settings.DiscussionWe investigated the emergence and epidemiology of
moxiﬂoxacin-resistant C. difﬁcile RT231 in Sweden betweenobiology and Infectious Diseases, NMNI, 14, 58–66
nses/by-nc-nd/4.0/).
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FIG. 2. Neighbour-joining tree of Clostridium difﬁcile RT231 isolates
circulating in Sweden between 2006 and 2015. Samples are colour
coded according to year of isolation: 2006 (blue), 2007 (green), 2008
(red) and 2009 to 2015 (black).
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of this moxiﬂoxacin-resistant type to county-speciﬁc moxi-
ﬂoxacin prescription rates. A majority of RT231 isolates iden-
tiﬁed in Sweden since 2006 have been moxiﬂoxacin resistant
(98%, 186/189). The proportion of moxiﬂoxacin resistance
among all C. difﬁcile isolates has been around 15% in Sweden
between 2009 and 2015 (range, 10–21%), which is less than
previously reported: 40% in Europe [21]. The amino acid sub-
stitution (Thr82 > Ile in gyrA gene) is the most frequently
described mutation associated with ﬂuoroquinolone-resistant
C. difﬁcile, including the hypervirulent ribotype 027 [20]; it
was also present in all moxiﬂoxacin-resistant RT231 isolates
studied. Although association between multiple substitutions
and high-level moxiﬂoxacin resistance have been previously
demonstrated [22], all resistant isolates of RT231 included in
our study harboured only a single mutation and showed high-
level resistance (MIC >32 mg/L). Interestingly, most of the© 2016 The Author(s). Published by Elsevier Ltd on behal
This is an open access articTN5398 transposon was detected, but with a deletion of the
ermB gene locus, known to confer macrolide and lincosamide
resistance [23]. No mutations were found in the 23S rRNA
sequence. Macrolide and lincosamide resistance is thus most
likely conferred by an as-yet unknown mechanism. Although
isolates belonging to clusters 2 and 3 carried mutations in the
L4 or L22 proteins of the 50S ribosomal subunit—proteins
associated with macrolide resistance [24,25]—the closely
related isolates in cluster 1 have L4 and L22 proteins identical
to the erythromycin-sensitive strains, and we believe that an
evolution of separate resistance mechanisms is unlikely.
Although C. difﬁcile RT231 was ﬁrst identiﬁed in a Stockholm
hospital as early as in 1999, it remained a rare type until the
outbreak was identiﬁed in Stockholm county in 2008 [12,26].
On the basis of the previously estimated evolutionary rate of
0.74 SNP per year for C. difﬁcile, up to 3 SNPs per genome
would be expected to be seen between related isolates
collected up to 365 days apart [27]. By using these previous
estimates of C. difﬁcile evolution, we concluded that the ﬁrst
two RT231 strains are likely related and originated from a
common ancestor. These isolates were isolated almost by a 2-
year gap in Stockholm (CD901, cluster 2; MX3, cluster 1) and
harbour 6 SNP differences in between. In contrast, two
genetically distinct C. difﬁcile genotypes were also shown to be
circulating in Stockholm in 2008, as demonstrated by more than
10 SNPs’ difference between the isolates (MX70 and MX381).
Interestingly, a third genetically distinct C. difﬁcile genotype
(MX165) differing from MX70 by ﬁve nucleotides was also
identiﬁed in Stockholm during the same year. This shows that at
least two divergent sublineages of moxiﬂoxacin-resistant
C. difﬁcile RT231 were already circulating in the Stockholm
area when the outbreak was found in 2008, and other strains
related to these outbreak strains had likely been circulating in
the area years before that. The continued circulation of a clonal
strain, demonstrated both in the Stockholm and Uppsala–
Örebro healthcare regions, suggests that RT231 strains can
persist for a long time in healthcare settings. Because the spread
of clonal strains (deﬁned as 1 SNP difference) occurred
mainly within a healthcare region, patient movement through
hospitals with specialized care is presumably the main trans-
mission route for spreading C. difﬁcile RT231. It is therefore
important to implement strict cleaning procedures and isolation
routines for all patients infected with moxiﬂoxacin-resistant
strains to stop further transmission.
Spread of RT231 was noted in Stockholm county in 2008,
but the emergence had likely already occurred few years before
that. It is unclear why it emerged particularly in the Stockholm
area, where the prescription rate of moxiﬂoxacin has not been
the highest in Sweden. However, it is important to note that the
reduced use of moxiﬂoxacin in Stockholm county has coincidedf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 14, 58–66
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FIG. 3. Deletion of ermB gene locus in Clostridium difﬁcile RT231 isolate MX70 mapped against TN5398 transposon.
64 New Microbes and New Infections, Volume 14 Number C, November 2016 NMNIwith a reduction in the spread of RT231 in the area and the
increased moxiﬂoxacin use in Uppsala county with the
increased spread of this moxiﬂoxacin-resistant type. Similarly,
the counties of Jönköping and Kronoberg, which had highFIG. 4. Prescription of moxiﬂoxacin in community (a) and hospital (b) setti
hospital setting is incomplete for Jönköping, 2013–2015.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Micr
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceprescription rates of moxiﬂoxacin between 2005 and 2010,
were affected by outbreaks of moxiﬂoxacin-resistant C. difﬁcile
other than RT231: RT046 and RT027 respectively [13,28]. In
the county of Jönköping, as prescription rates dropped andngs by county in Sweden between 2005 and 2015. Prescription data in
obiology and Infectious Diseases, NMNI, 14, 58–66
nses/by-nc-nd/4.0/).
NMNI Harvala et al. C. difﬁcile ribotype 231 in Sweden 65infection control was implemented, RT046 has virtually been
eliminated from the area [28].
Interestingly, in a case–control study in Stockholm county,
ﬂuoroquinolones were identiﬁed as a statistically signiﬁcant risk
factor for acquiring RT231 CDI, but only a small proportion of
individuals infected with this strain had actually received mox-
iﬂoxacin (Zomer et al., unpublished data). This is keeping with
the idea that general antibiotic pressure in the community plays
a major role in driving the emergence of resistant strains of
C. difﬁcile, and, as in the case of moxiﬂoxacin-resistant RT231,
further use of any ﬂuoroquinolone will likely lead to CDI
problems in infected individuals [29]. A qualitative goal for
limiting ﬂuoroquinolone prescribing in outpatient care in Swe-
den was set in 2007, but none of the counties has reached the
target set (https://www.folkhalsomyndigheten.se/pageﬁles/
24127/Swedres-Svarm-2015-15099.pdf).
A limitation of this study is the lack of information regarding
the number of cases and patient hospitalizations (i.e. a move to
another hospital). This study may also contain multiple isolates
from the same individuals, so the real number of cases cannot
be determined. In addition, because routine surveillance was
established in Sweden in 2009, isolates collected before 2009
were not systematically collected. As a further limitation, age-
speciﬁc moxiﬂoxacin and general ﬂuoroquinolone consump-
tion rates were unavailable for study.
In conclusion, we used SNP analysis based on WGS to
investigate the emergence and spread of moxiﬂoxacin-resistant
C. difﬁcile RT231 in Sweden over a 10-year study period. We
demonstrated the continued transmission of RT231 within and
between different close-proximity counties. The outbreak
emerged ﬁrst in the Stockholm area and spread to surrounding
counties in the Uppsala–Örebro healthcare region. Our results
support the need for careful monitoring of hospitalized in-
dividuals infected with moxiﬂoxacin-resistant C. difﬁcile types as
well as for stricter limits on ﬂuoroquinolone prescriptions in
Sweden. Although RT231 has only been described in Sweden so
far, it can potentially spread to countries where other
moxiﬂoxacin-resistant C. difﬁcile types have also recently
emerged. The factors associated with the emergence of new
ribotypes within a certain country remain largely unexplored.AcknowledgementsWe acknowledge all the clinical microbiologic laboratories
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